Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) EBITDA Margin (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBITDA Margin for 17 consecutive years, with 0.35% as the latest value for Q1 2026.

  • Quarterly EBITDA Margin rose 247.0% to 0.35% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 1.81% through Jan 2026, down 206.0% year-over-year, with the annual reading at 1.86% for FY2026, 200.0% down from the prior year.
  • EBITDA Margin for Q1 2026 was 0.35% at Usana Health Sciences, up from 3.02% in the prior quarter.
  • The five-year high for EBITDA Margin was 10.54% in Q4 2023, with the low at 3.02% in Q3 2025.
  • Average EBITDA Margin over 5 years is 4.8%, with a median of 4.5% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 420bps in 2024, while the deepest fall reached -1265bps in 2024.
  • Over 5 years, EBITDA Margin stood at 8.78% in 2022, then grew by 20bps to 10.54% in 2023, then plummeted by -120bps to 2.11% in 2024, then crashed by -43bps to 3.02% in 2025, then surged by 112bps to 0.35% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 0.35%, 3.02%, and 5.54% for Q1 2026, Q3 2025, and Q2 2025 respectively.